At this time, I would like to welcome everyone to the Eagle Pharmaceuticals second quarter 2022 financial results. It is now my pleasure to turn the floor over to Ms. Lisa Wilson, investor relations for Eagle Pharmaceuticals. This is Lisa Wilson, investor relations for Eagle Pharmaceuticals.
Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of -50.16% and 31.44%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
• Q2 2022 net loss was $(0.74) per basic and diluted share and adjusted non-GAAP net income was $1.58 per basic and $1.56 per diluted share • Total revenue for Q2 2022 was $74.1 million, compared to $48.1 million in Q2 2021, primarily reflecting product sales of vasopressin and PEMFEXY® • First half 2022 adjusted non-GAAP earnings per diluted share1 more than doubled to $5.60 from full year 2021 adjusted non-GAAP earnings per diluted share, outperforming any full year in the Company’s history •